Practice Impact Extra

Recent studies examine the association between mital valve prolapse and sudden cardiac death.

Sudden Cardiac Death in Heart Failure trial takes a look at effective therapies for this devastating event.

Prevention Guidelines published by the ACC/AHA are not gendered. Should cardiologists be looking at a different set of risk factors for cardiovascular disease in women?

Researchers examine whether self-reported physical activity characterized as low, moderate or high reduced the mortality risk associated with coronary plaque burden measured by CAC score.

Researchers examine whether Transcatheter Mitral Valve Clip can improve clinical outcomes in patients with severe functional mitral valve regurgitation.

Bempedoic Acid has shown promising results in the treatment of patients with high LDL levels. Should there be any concern in its use to treat patients with diabetes?

Myocardial injury caused by Covid 19 continues to be reported in hospitalized patients. Researchers are analyzing MRI data to determine sustained cardiac involvement after a patient’s recovery.

Evidence regarding various oils and their effect on LDL cholesterol and other CV risk modifiers can be controversial as is the case with coconut oil consumption. A closer look at coconut’s long-chain fatty acids explains the potential CVD risk of this trendy oil.

The development of monoclonal antibody PCSK9 inhibitors has allowed for dramatic lowering of LDL and CV events, but what new analysis adds knowledge to the benefits of PCSK9? Dr. Bernie reviews the practice impacting results of a prespecified analysis of FOURIER trial published in JAMA-Cardiology April 2020, to evaluate the LDL cholesterol-lowering effect of Evolocumab on different types and sizes of myocardial infarction.

A 2016 study from Washington University School of Medicine in St. Louis showed that long term use of VKA’s (Warfarin), led to a 25% increase incidence of fracture. When Direct Oral Anticoagulants, DOAC’s, were developed their great benefit was that they did not inhibit vitamin K and adversely affect bone density. A study in December 2019 is the latest assessment as to whether these new blood thinners are actually lowering the risk fractures in the elderly.